Condition: Stage III NSCLC · Sponsor: Fondazione Ricerca Traslazionale
A Ph.2, single-arm, monocentric, trial of neo-adjiuvant chemo-immunotherapy for stage III, PD-L1 positive, NSCLC. Adults and smokers (past or current) diagnosed with stage III NSCLC without driver molecular alterations (EGFR, ALK, ROS1, RET).
This description comes directly from the study's public registry record.
Federico Cappuzzo, Medical Oncology · +390652665789 · federico.cappuzzo@fondazionefort.org
Always discuss trial participation with your own doctor first.
| Istituti Fisioterapici Ospitalieri | Rome, Roma (RM), Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07264647